AstraZeneca’s cancer drug pipeline suffered a setback when the experimental drug selumetinib failed to meet its goal in a late-stage trial for lung cancer.
Amgen wins EU green light for first virus-based cancer drug
Approvals, Approvals, BRAF V600 Inhibitors, BRAF V600 inhibitors, Cancer Cells, EMA, FDA, FDA/Regulatory, Health, Herpes, Herpes Simplex Virus, Immune Response, Immunotherapies, Immunotherapy, M&A, M&A, MEK Inhibitors, MEK Inhibitors, Melanoma, New Drug ApprovalsA first-in-class drug from Amgen based on a tumor-killing virus was given a green light by European regulators on Friday, paving the way for its approval within a couple of […]